Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity.
Watts, E., Heidenreich, D., Tucker, E., Raab, M., Strebhardt, K., Chesler, L., Knapp, S., Bellenie, B., Hoelder, S.(2019) J Med Chem 62: 2618-2637
- PubMed: 30789735 
- DOI: 10.1021/acs.jmedchem.8b01947
- Primary Citation of Related Structures:  
6Q3Y, 6Q3Z - PubMed Abstract: 
Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) is a potential therapeutic strategy for targeting two key oncogenic drivers that co-segregate in a significant fraction of high-risk neuroblastoma patients, mutation of ALK and amplification of MYCN ...